Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;11(3):693-696.
doi: 10.1111/1759-7714.13319. Epub 2020 Feb 5.

S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501

Minoru Fukuda  1 , Soichiro Funaki  2 , Takuya Yamazaki  3 , Shuntaro Sato  4 , Hiroshi Mukae  5 , Mitsuhiro Takenoyama  6 , Junya Fukuoka  7 , Kazuki Nabeshima  8 , Hisashi Tateyama  9 , Kazuto Ashizawa  10 , Masaki Hara  11 , Takashi Seto  6 , Meinoshin Okumura  12   13 , Kenji Sugio  14   15
Affiliations

S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501

Minoru Fukuda et al. Thorac Cancer. 2020 Mar.

Abstract

Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S-1 treatment is effective against thymic carcinoma. S-1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non-small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression-free survival, and safety.

Keywords: Cisplatin; S-1; radiotherapy; thymic carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study schema.
See this image and copyright information in PMC

References

    1. Bretti S, Berruti A, Loddo C et al Multimodal management of stage III‐IVa malignant thymoma. Lung Cancer 2004; 44: 69–77. - PubMed
    1. Shirasaka T, Nakano K, Takechi T et al Antitumor activity of 1 M tegafur‐0.4 M 5‐chloro‐2,4‐dihydroxypyridine‐1 M potassium oxonate (S‐1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602–6. - PubMed
    1. Kawahara M, Furuse K, Segawa Y et al Phase II study of S‐1, a novel oral fluorouracil, in advanced non‐small‐cell lung cancer. Br J Cancer 2001; 85: 939–43. - PMC - PubMed
    1. Miyamoto S, Boku N, Ohtsu A et al Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S‐1). Study group of S‐1 for gastric cancer. Int J Oncol 2000; 17: 653–8. - PubMed
    1. Ono A, Naito T, Yamamoto N. S‐1 treatment for chemorefractory thymic carcinoma. J Thorac Oncol 2008; 3: 1076. - PubMed

Publication types